Tumor vascular endothelial cells expressing alpha-gal epitope and shared vasculature-associated antigens (TVEC-alpha-gal/SVAA)

Tumor vascular endothelial cells expressing the alpha-gal epitope and shared vasculature-associated antigens (SVAA) represent a specialized cellular target in cancer immunotherapy designed to disrupt the tumor's blood supply and stimulate a systemic immune response (Galili, U., Expert Opin Biol Ther, 2013). The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) is a carbohydrate structure absent in humans but present in other mammals, leading to the natural production of high-titer anti-Gal antibodies in the human population (Galili, U., Immunol Cell Biol, 2005). By engineering tumor-associated endothelial cells to express this epitope, therapies like ValloVax aim to trigger a hyperacute rejection-like response, where natural antibodies bind to the tumor vasculature and activate the complement cascade, resulting in vascular collapse and tumor necrosis (Lamas, S. O., et al., J Transl Med, 2015). This approach is often combined with the presentation of shared vasculature-associated antigens—such as VEGFR or TEMs—to stimulate a broader, long-lasting T-cell mediated immune response against the tumor's supporting infrastructure. This dual mechanism not only causes immediate physical destruction of the tumor's nutrient supply but also promotes an in situ vaccination effect as tumor-specific antigens are released into an inflammatory environment.

Other names

Alpha-gal modified tumor vasculatureSVAA-expressing endothelial cellsGal alpha 1-3Gal beta 1-4GlcNAc-R expressing tumor vesselsValloVax target cells

Induction of a hyperacute rejection-like response through the binding of natural anti-Gal antibodies to the alpha-gal epitope on tumor vascular endothelial cells, leading to complement-mediated lysis, vascular collapse, and subsequent T-cell activation against shared vascular antigens.